Optically Active Butyric Acid Synthesis via Chiral Lactone
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing optically active butyric acid compounds for PPARα activation suffer from low yield and purity, which is crucial for treating hyperlipidemia, arteriosclerosis, diabetes, and related conditions without causing obesity or weight gain.
Innovation Solution
A process involving phenyl-etherification of optically active 2-trifluoromethanesulfonyloxybutyrolactone or 2-hydroxybutyrolactone under Mitsunobu reaction conditions, followed by lactone ring opening, dehalogenation, and de-esterification to produce the compound with high yield and optical purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional phenyl-etherification methods are used to produce optically active butyric acid compounds, then the production process is simple, but the yield and optical purity are low
Solution Approach 1:
The patent changes the chemical parameters of the reaction system by using optically active 2-trifluoromethanesulfonyloxybutyrolactone as a chiral starting material and selecting specific base catalysts (triethylamine, diisopropylethylamine, or pyridine) to achieve high optical purity (90% ee or more) in the phenyl-etherification reaction, thereby resolving the contradiction between process simplicity and manufacturing precision
Solution Approach 2:
The patent prepares optically active 2-trifluoromethanesulfonyloxybutyrolactone as a pre-synthesized chiral intermediate with defined stereochemistry before performing the phenyl-etherification reaction. This preliminary preparation of the chiral building block ensures that the final product achieves high optical purity without requiring complex chiral resolution steps during the main synthesis
2Device complexity
If conventional phenyl-etherification methods are used, then the synthesis steps are fewer, but the production yield is low
Solution Approach 1:
The patent optimizes reaction parameters including using a 1:1.05 molar ratio of phenol to starting material, selecting specific bases (triethylamine, diisopropylethylamine, or pyridine) as catalysts, and conducting the reaction in dichloromethane or chloroform solvent to achieve high conversion and yield (80% or more) while maintaining the two-step synthetic route
Solution Approach 2:
The patent employs readily available, inexpensive reagents such as common bases (triethylamine, diisopropylethylamine, pyridine) and standard solvents (dichloromethane, chloroform) that can be easily handled and disposed of, making the process industrially viable while achieving high yields without requiring expensive or complex reagents
3Reliability
If PPARα-selective activators are developed to treat hyperlipidemia and related diseases, then therapeutic effectiveness is improved, but the risk of obesity and weight gain increases due to PPARγ activation
Solution Approach 1:
The patent introduces chiral centers into the butyric acid compound structure to create enantiomers with different biological activities. By selecting and optimizing the optically active form, the patent achieves high PPARα selectivity (therapeutic effectiveness) while minimizing PPARγ activation (obesity risk), thereby resolving the contradiction through stereochemical differentiation of biological effects
Solution Approach 2:
The patent divides the butyric acid compound into distinct structural segments including a chiral center with specific stereochemistry, a phenyl ether moiety, and a carboxylic acid group. This structural segmentation allows independent optimization of PPARα activation (therapeutic effect) while minimizing PPARγ interaction (adverse effect), achieving selective pharmacological activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high-yield and high-purity production of optically active butyric acid, ensuring effective PPARα activation for treating hyperlipidemia, arteriosclerosis, diabetes, and related conditions without obesity or weight gain.
Implementation Method 1
reacting optically active 2-trifluoromethanesulfonyloxybutyrolactone (2a) with a phenol form (1) in the presence of a base
Implementation Method 2
reacting optically active 2-hydroxybutyrolactone (2b) under Mitsunobu reaction conditions
Implementation Method 3
The lactone ring of compound (3) is opened to form compound (4) (step 2)
Implementation Method 4
compound (4) is dehalogenated to form compound (5) (step 3)
Implementation Method 5
followed by de-esterification (step 4)
Data Source
AI summary
The invention provides a process for producing an optically active butyric acid compound and a production intermediate therefor at high yield and high purity. The present invention provides a process for producing Compound (6), including reacting Compound (1) with optically active 2-trifluoromethanesulfonyloxybutyrolactone (2a) in the presence of a base or reacting optically active 2-hydroxybutyrolactone (2b) under Mitsunobu reaction conditions, to thereby form Compound (3); reacting Compound (3) with an alcohol and a halogenating agent, to thereby form Compound (4) ; dehalogenating Compound (4), to thereby form Compound (5); and de-esterifying Compound (5).